These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12755849)

  • 21. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The European Schizophrenia Outpatient Health Outcomes Study: observational study over 36 months of the French cohort of schizophrenic outpatients treated with antipsychotics].
    Gasquet I; Chartier F; Tcherny-Lessenot S; Lépine JP
    Rev Epidemiol Sante Publique; 2009 Feb; 57(1):25-32. PubMed ID: 19162420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of the findings from the European SOHO study.
    Suarez D; Haro JM
    Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
    Leslie DL; Rosenheck R
    J Nerv Ment Dis; 2001 Jun; 189(6):377-83. PubMed ID: 11434638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia].
    De Beauchamp I; Giraud-Baro E; Gury C
    Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Haro JM; Edgell ET; Novick D; Alonso J; Kennedy L; Jones PB; Ratcliffe M; Breier A;
    Acta Psychiatr Scand; 2005 Mar; 111(3):220-31. PubMed ID: 15701107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Novick D; Haro JM; Perrin E; Suarez D; Texeira JM
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):542-50. PubMed ID: 19500949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine: an atypical antipsychotic for schizophrenia.
    Lund BC; Perry PJ
    Expert Opin Pharmacother; 2000 Jan; 1(2):305-23. PubMed ID: 11249551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
    Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
    Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
    Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
    Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
    Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
    Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR
    Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Atypical antipsychotics].
    Naber D
    Nervenarzt; 2000 May; 71(5):327-8. PubMed ID: 10846707
    [No Abstract]   [Full Text] [Related]  

  • 35. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study.
    Alonso J; Croudace T; Brown J; Gasquet I; Knapp MR; Suárez D; Novick D
    Value Health; 2009 Jun; 12(4):536-43. PubMed ID: 19900255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.